Introduction
Patients with cancer are often treated with a multimodality approach. Toxicity may arise not only from treatment of tumors in the gastrointestinal tract but also from the systemic effects of chemotherapy used to treat leukemia, renal cell carcinoma, and ovarian tumors. Understanding the mechanism of action of chemotherapeutic agents may help radiologists recognize potential complications that may arise. Knowledge of the type and timing of radiation therapy is essential for radiologists to avoid misinterpreting posttherapeutic change as recurrent tumor. Typically, computed tomography (CT) is the primary imaging modality for diagnosis, staging, and follow-up of cancer, and most complications may be identified at CT. However, newer imaging modalities, such as magnetic resonance (MR) imaging and positron emission tomography (PET)/CT, complement CT and have higher specificity for depicting recurrent tumor. In this article, we review the mechanism of action of chemotherapeutic agents, including newer targeted agents; discuss the timing and types of radiation that affect gastrointestinal organs; and provide imaging examples of the complications of therapy and recurrent tumors. sites and works by preventing activation of these pathways and tumor cell growth. It is used to treat patients with leukemia and gastrointestinal stromal tumors. Side effects include bleeding and fluid retention. Bevacizumab is a kinase inhibitor that binds to the VEGF receptor and works by preventing tumor molecules from binding to the VEGF receptor and, thus, angiogenesis. Currently, it is used to treat patients with colorectal carcinoma, glioblastoma, and other cancers, and its side effects include perforation, hypertension, and thrombosis. EGF receptor (EGFR) inhibitors bind to the EGFR and prevent binding of EGF. Cetuximab is a monoclonal antibody used to treat those with EGFR-expressing colorectal carcinoma, lung carcinoma, and squamous cell carcinoma of the head and neck. Colitis is a potential side effect (1) . Multitarget RTK inhibitors block signal transduction and angiogenesis and include sunitinib and sorafenib. Both are used to treat patients with renal cell carcinoma, and sorafenib is now being used to treat patients with unresectable hepatocellular carcinoma. Side effects of sunitinib and sorafenib include pancreatitis and enteritis.
Immune system-targeted drugs, such as CTLA4 inhibitors, are used to treat patients with refractory melanoma and solid tumors. Usually, CTLA4 is on the surface of the T cell and binds with B7 to deactivate the T cell. Drugs such as ipilimumab bind to the CTLA4 receptor, preventing deactivation and promoting activation of T cells, which results in antitumor immunity. Side effects include colitis, hypophysitis, and hepatitis and usually indicate that therapy is working (Tables 2, 3 ).
Radiation Therapy
Most tumors of the gastrointestinal tract (eg, the esophagus, pancreas, stomach, and rectum) are managed with external beam radiation. The difficult balance in radiation therapy is to give the greatest dose to the tumor and limit the side effects to adjacent organs. The most common therapy is three-dimensional-conformal radiation therapy (3D-CRT). In the past decade, several new technologies have been developed that will, hopefully, decrease morbidity and increase curative function (2) . These new technologies include intensity-modulated radiation therapy (IMRT), which allows better control of the radiated area than conventional 3D-CRT, and stereotactic body radiation therapy (SBRT), which is used to treat localized tumors of the lung and liver. Acute effects from radiation therapy usually occur in the first 3 months after therapy, and late effects usually occur 1 year after therapy. Acute effects may be a precursor for development of late effects.
Chemotherapeutic Agents
Classic chemotherapeutic agents cause cell death and damage by targeting rapidly growing cells. The mechanism of action of the classic agents includes interruption of the cell cycle and synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). However, in addition to targeting rapidly growing cancer cells, cytotoxic agents also affect the cells in bone marrow and the gastrointestinal tract. The combination of immunosuppression and damage to cells in the gastrointestinal tract may cause complications. The most commonly used cytotoxic therapies in oncology are alkylating agents, antimetabolites, antibiotics, topoisomerase inhibitors, mitotic inhibitors, steroids, and differentiating agents. Alkylating agents cause DNA damage and prevent cell division and replication. Examples of alkylating agents include cyclophosphamide; busulfan; dacarbazine; ifosfamide; and platinum drugs, such as cisplatin, carboplatin, and oxaliplatin. Antimetabolites work by damaging nucleotides during the S phase of the cell cycle and include 5-fluorouracil, methotrexate, and gemcitabine. Antibiotics act by inhibiting enzymes that aid in DNA replication; doxorubicin and bleomycin are in this category. Topoisomerase inhibitors derive from plant alkaloids and interfere with DNA unwinding. Topotecan and irinotecan are topoisomerase type I inhibitors, and etoposide and teniposide are type II inhibitors. Mitotic inhibitors affect mitosis and include paclitaxel, docetaxel, vincristine, and vinblastine.
Newer targeted therapies that have been developed cause apoptosis by changing proteins within the cell or inhibiting angiogenesis to decrease blood supply to the tumor by acting on growth factors, the tyrosine kinase receptors (RTK) of growth factors, or the involved pathways in the cell to target those that are involved in tumor cell growth. When proliferating tumor cells become hypoxic, hypoxia-inducible factor alpha (HIF-1A) is activated, and other growth factors, cytokines, and oncogenes are produced to increase production of HIF-1A. Examples of growth factors include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). These growth factors bind to tyrosine kinase receptors on endothelial cells, which activates other enzymes, such as phosphoinositide 3-kinase (PI3 K) and mitogenactivated protein kinase (MAPK), and increases production of HIF-1A and, subsequently, vascular endothelial growth factor (VEGF) in endothelial cells, causing angiogenesis (Table 1) .
Imatinib is a tyrosine kinase inhibitor that is specific for the Bcr-Abl, c-kit and PDGF-R in patients who are predisposed to fatty liver, especially those who may be eligible for liver resection. Hepatic steatosis greater than 30% has been linked to increased morbidity after liver resection. The presence of steatohepatitis has been associated with a higher 90-day mortality rate of 15% compared with 2% in patients who undergo resection (5, 6) . At imaging, steatosis may be focal or diffuse. Typical locations of focal fat deposition include the falciform ligament, porta hepatis, and gallbladder fossa. Areas of fatty change may be geometric and well defined. At unenhanced CT, the attenuation difference between the liver and the spleen (that in the liver minus that in the spleen) is -5 to -10 HU or less. At contrast materialenhanced CT, an attenuation difference of -17 HU in the late phase is optimal for depicting fat deposition (7) . It may be difficult to differentiate fat from metastasis if fat infiltration occurs in unusual or unexpected locations. In these cases, MR imaging performed both in-and out-ofphase with fat suppressive techniques may help distinguish fatty infiltration from metastases (Fig 1) . It is important to alert the clinician if findings of steatosis or steatohepatitis are present because chemotherapy may be altered to prevent further liver damage.
Hepatic Capsular Retraction.-Hepatic capsular retraction (pseudocirrhosis) is seen in as many as 50% of patients with breast cancer who undergo chemotherapy. It is also seen in those with carcinoid tumor and Hodgkin disease. In those with breast cancer, capsular retraction is associated with large hepatic metastases and a change in size-either a decrease from a response to chemotherapy or an increase from disease progression. Pseudocirrhosis results from distortion of the normal hepatic lobular pattern, which usually results from diffuse nodular regenerative hyperplasia (8) .
At CT and MR imaging, initial loss of the normal convex edge of the liver is seen, with flattening or development of concavity in the presence of hepatic metastatic disease. In later stages, the imaging appearance of hepatic capsular retraction may be similar to that of cirrhosis (a pseudocirrhosis pattern), with capsular retraction and replacement of the normal parenchyma by scarring and fibrosis (Fig 2) (9) . Ascites and splenomegaly may be present. It is important to recognize capsular retraction as a posttreatment complication rather than cirrhosis. Treatment includes cessation of chemotherapy, which may reverse the clinical findings.
Portal Vein Thrombosis.-Portal vein branch thrombosis may occur after chemotherapy or surgery and is associated with FOLFIRI and bevacizumab therapy for treatment of colorectal cancer metastases (10). Bevacizumab decreases the healing capacity of endothelial cells, which causes bleeding and thrombosis. The mechanism by which irinotecan may cause thrombosis is unknown. Patients with portal vein thrombosis are usually asymptomatic. At imaging, portal vein thrombosis is seen as a filling defect in the portal vein branch with an associated wedge-shaped area of increased enhancement in the arterial phase that becomes isoattenuating relative to the liver in the portal venous and delayed phases, a result of vascular occlusion (Fig 3) . Portal vein thrombosis is distinct from metastatic disease given its sharp demarcation and wedge shape. Treatment consists of anticoagulation therapy and ceasing chemotherapy.
Hepatic Veno-occlusive Disease.-Hepatic venoocclusive disease, more recently referred to as sinusoidal obstruction syndrome, is vascular congestion of the liver caused by sinusoidal injury (11) . Pathologically, damage to the endothelial cells is seen on the sinusoidal surface of the hepatocytes, which leads to fibrosis of the sinusoids and hepatocyte necrosis, which, in turn, leads to occlusion of the hepatic venules. Hepatic venoocclusive disease is more commonly associated with stem cell transplantation and high-dose chemotherapy in patients with leukemia (12) . It occurs as a complication of treatment in 10%-60% of patients who undergo stem cell transplantation and usually occurs by day 35, although it may occur later. Now, hepatic veno-occlusive disease occurs with conventional chemotherapeutic agents and is seen in 54% of patients with metastatic colorectal carcinoma who undergo oxaliplatin therapy (11, 13, 14) . There does not appear to be a relationship between the dose and the incidence of sinusoidal obstruction. Patients may present with hepatic failure, abdominal pain, tender hepatomegaly, and jaundice. Clinically, these features may be similar to those of graft-versus-host disease; biopsy may be necessary to differentiate these conditions (15) .
Enlargement and heterogeneity of the liver, ascites, and gallbladder wall thickening are seen at ultrasonography (US). Hepatic venous flow may be decreased. At CT, heterogeneity of the liver, periportal edema, ascites, and narrowing of the right hepatic vein are more suggestive of venoocclusive disease than graft-versus-host disease. Small bowel wall thickening is an important feature because it is associated with graft-versus-host disease (16) . In addition, splenomegaly and varices indicate portal hypertension (Fig 4) . There is no effective treatment for hepatic veno-occlusive disease. Given its significant morbidity and mortality, the focus is on prevention with drugs such as tacrolimus (17) . In patients with metastatic colorectal cancer who are undergoing oxaliplatin therapy, it has been suggested that bevacizumab has a partially protective effect (18, 19) .
Hepatic Congestion.-Hepatic congestion may be seen in association with chemotherapy-induced congestive heart failure. Associated agents that are cardiotoxic and lead to congestive heart failure include anthracycline-based drugs and new tyrosine kinase inhibitors, such as imatinib and dasatinib (20) . Hepatic congestion manifests with dyspnea, hepatomegaly, jaundice, pain, and mild elevation of liver enzymes At imaging, diffuse mottled heterogeneous enhancement of the liver is seen, possibly only in the initial phase, with retrograde opacification of the inferior vena cava and hepatic veins (Fig 5) .
Findings in the thorax that support a diagnosis of hepatic congestion include pulmonary venous hypertension, pulmonary edema, pleural and pericardial effusions, and cardiomegaly. Treatment includes cessation of the inciting agent and supportive measures.
Spleen
Splenic Rupture.-Typically, rupture of the spleen is associated with high-dose induction chemotherapy in patients with leukemia and those who are receiving granulocyte macrophage colony stimulating factors (21) . There are reports of splenic rupture from the VEGF agent imatinib in patients with leukemia (22) . In addition, use of high-dose chemotherapeutic agents, colony stimulating factors, and VEGF agents in conjunction with antico- Axial CT image obtained 6 months after therapy shows a decrease in the size of the hepatic metastases but an increase in splenic size. Because of the presence of thrombocytopenia, oxaliplatin therapy was halted. Usually, thrombocytopenia regresses once therapy is stopped; however, in this case, sequestration of platelets continued, and splenic arterial embolization was performed.
agulation therapy may lead to spontaneous splenic bleeding. The clinical manifestation of splenic rupture includes hypotension, tachycardia, abdominal pain, and nausea resulting from hemoperitoneum. At CT, splenic rupture is seen as an area of low attenuation within the spleen with blood in the abdomen. It may extend into the paracolic gutter. Unclotted blood may have attenuation of 30-45 HU, and clotted blood may have slightly higher attenuation of 45-70 HU on both unenhanced and contrast-enhanced images (Fig 6) . Active splenic bleeding is seen as extravasation of intravenous contrast material with attenuation of 85-370 HU (average, 132 HU) in the arterial phase (23) . The presence of active bleeding requires urgent treatment with surgery or embolization. Transfusion may be required.
Therapy-induced Splenomegaly.-Progressive enlargement of the spleen with associated thrombocytopenia results from hepatic sinusoidal injury, which leads to portal hypertension. Chemotherapeutic agents, such as the oxaliplatin component of the leucovorin-fluorouracil-oxaliplatin (FOLFOX) regimen for colorectal carcinoma metastases, are responsible for inciting the hepatic injury (24) . Patients may present with abdominal pain, elevated liver enzyme levels, portal hypertension, and thrombocytopenia. Splenic sequestration of platelets causes thrombocytopenia. At imaging, the spleen increases in size as therapy continues and may be used as a marker for development of portal hypertension in patients who are undergoing FOLFOX therapy. Additional signs of portal hypertension include enlargement of the portal vein and development of varices (Fig 7) . Although beta blockers may be used to treat portal hypertension, thrombocytopenia and severe varices are contraindications. In patients with severe thrombocytopenia, oxaliplatin therapy should be stopped, and splenic embolization may be performed (25) .
Spleen after Use of Thorotrast.-Thorotrast is a contrast material that was used for radiographic 
be carcinogenic. Thorotrast is radioactive and emits alpha particles and products of decay into the body tissues, particularly the reticuloendothelial system, which lead to functional asplenia. In patients in whom Thorotrast was used, the spleen has diffuse high attenuation at imaging (Fig 8) .
Other organs, such as the liver and lymph nodes, may be involved and have similar high attenuation indicative of Thorotrast accumulation. There is no specific treatment for Thorotrast accumulation. Thorotrast has been associated with secondary malignancies, such as biliary duct cancer and leukemia; thus, a careful search for other lesions should be performed (26) .
Pancreas
Pancreatitis may occur as a complication of chemotherapy or surgery. Causative chemotherapeutic agents include asparaginase, ifosfamide, paclitaxel, cisplatin, vinorelbine, cytarabine, and tretinoin (27) . Asparaginase-associated pancreatitis has a prevalence of approximately 2%-16% (27,28). Butt et al described six cases of oxaliplatin-induced pancreatitis (29) . The tyrosine kinase inhibitors sorafenib and sunitinib, which are used to treat renal cell carcinoma, may cause pancreatitis (30) . Symptoms may occur hours after administration of chemotherapy, but they may also be delayed, occurring 1 month after therapy. Cytoreductive surgery with intraperitoneal chemotherapy, which is used to treat pseudomyxoma and metastatic peritoneal disease, may also cause pancreatitis (31) . Patients may present with abdominal pain and elevated lipase and amylase levels. In many cases, chemical pancreatitis with no imaging findings is present. At CT, pancreatitis is seen as areas of low attenuation or diffuse edema in the pancreas, with peripancreatic fat stranding and peripancreatic fluid. Treatment is usually supportive, and, given the high risk for mortality, alternate chemotherapy is administered if necessary (27) .
Bowel
Enteritis.-Enteritis may occur as a result of chemotherapy and, according to the literature, is most commonly associated with fluorouracil and leucovorin. Fluorouracil targets rapidly dividing cells by inhibiting thymidine synthetase or incorporating itself into RNA (32) . Enteritis is also a side effect of EGFR inhibitors; the presence of an accompanying rash may provide clues to the toxicity of a therapy (33) . Patients with enteritis report a decreased appetite, nausea, and vomiting.
The ileum is most commonly involved, but enteritis may involve the entire small bowel (34) . At CT, enteritis is seen as small bowel wall thickening. The colon may also be involved. The bowel wall may exhibit the target sign, a result of submucosal edema and enhancement of the muscularis propria and mucosa, serosa, or both. Associated small bowel dilation and perforation may be present in severe cases. Usually, cessation of chemotherapy leads to resolution of symptoms.
Colitis.-Pseudomembranous colitis is an infectious condition of the bowel caused by immunosuppression, mucosal damage from chemotherapy, and superinfection with Clostridium difficile. Clinical manifestation of colitis consists of abdominal pain, nausea, and vomiting. CT findings include focal or diffuse colon wall thickening. Associated lymphadenopathy and pericolonic fat stranding may be present. Stool culture or endoscopy is used to confirm the diagnosis. Patients with pseudomembranous colitis are treated with antibiotic therapy and bowel rest with cessation of chemotherapy in severe cases.
Neutropenic colitis occurs in both adult and pediatric patients with hematologic malignancies, such as leukemia, and patients who are undergoing immunosuppressive therapy. In neutropenic colitis, chemotherapy causes damage to the colon mucosa, and neutropenia leads to bacterial infection and necrosis. Imaging helps exclude other causes of abdominal pain, such as appendicitis, other forms of colitis, and obstruction. At CT, neutropenic colitis usually manifests as bowel wall thickening of 3 mm or more and is localized to the terminal ileum and cecum CT image shows diffuse colonic wall thickening ( * ) and small reactive ileocolic nodes (arrows), findings consistent with pancolitis. Cessation of chemotherapy alleviated the symptoms. (Fig 9) . Pneumatosis and fluid or abscess formation may also be present. US may also be useful, especially in children.
Toxic megacolon is a rare but serious complication of neutropenic, pseudomembranous, and ulcerative colitis and most commonly occurs in patients who are untreated (35) . Toxic megacolon has been reported in those undergoing treatment for leukemia, breast cancer, and Hodgkin lymphoma. At radiography and CT, it is seen as dilation of the colon, and the colonic wall may appear "shaggy," with a loss of haustral contours. Toxic megacolon may lead to perforation, and associated pneumatosis, portal venous air, or pneumoperitoneum may be present. In cases of toxic megacolon, emergent surgery with hemicolectomy and ileostomy placement is warranted (36) .
Bowel Perforation, Fistulas, and Delayed Anastomotic Leak
Perforation and Fistula.-Antiangiogenic therapies, such as the antivascular VEGF agent bevacizumab and tyrosine kinase inhibitors sorafenib and sunitinib, are associated with bowel perforation. The incidence of perforation in patients who are undergoing bevacizumab-containing therapy is approximately 0.9%-4% (37, 38) . These drugs interfere with bowel microvasculature and cause ischemia and thrombosis of the vessels. Bevacizumab may also cause ulceration and poor healing of the mucosa, leading to perforation. Therefore, it should be used with caution in patients with serosal implants; implants adjacent to bowel in those with a preexisting ulceration; and weak bowel walls from an underlying condition such as Crohn disease, ulcerative colitis, tumor necrosis, and adjacent tumor. The risk for perforation is also higher in patients with colorectal carcinoma and renal cell carcinoma and in those receiving a higher dose. Bevacizumab has also been implicated in the development of fistulas and delayed anastomotic leaks after colonic resection. Other agents, such as capecitabine, are also associated with bowel perforation. Patients with bowel perforation present with vague abdominal pain and sepsis, usually within the first 6 months of treatment (38, 39) .
At CT, bowel discontinuity is seen, with surrounding air or contrast material, free intraperitoneal air, extraluminal fluid collections, and abscess formation. Fistulas may be seen with other loops of colon or small bowel, bladder, and vagina. If perforation is present, the inciting agent should be stopped and not reinitiated.
Delayed Anastomotic Leak.-Typically, postoperative anastomotic leaks occur within the first 3 months after surgery. When perforation occurs more than 1 year after surgery, recurrent tumor is usually suspected. However, delayed anastomotic leaks occur more than 1 year after surgery when antiangiogenesis therapy (eg, bevacizumab) has been administered. Clues to the diagnosis include a late onset of the leak compared with the date of surgery and the initiation of antiangiogenic therapy. Predisposing factors include preoperative radiation therapy, postoperative leak, and low anterior resection for rectal cancer (40) .
At CT, findings of anastomotic leak include dehiscence near the surgical clips, increased fluid adjacent to the anastomosis site, and colonic wall thickening. Signs of abscess formation and free intraperitoneal air may also be present. In patients with anastomotic dehiscence, there is no evidence of a mass to suggest tumor recurrence (Fig 10) . With tumor recurrence, there may be splaying of the sutures with a mass present. Treatment for anastomotic leak consists of cessation of chemotherapy and conservative management.
Graft-Versus-Host Disease.-Acute graft-versushost disease (GVHD) occurs within the first 100 days after bone marrow transplantation, with most cases occurring around the time of engraftment, at approximately 3 weeks. Hyperacute GVHD may occur even earlier in patients who have a severe mismatch or in whom prophylaxis was inadequate. Patients may present with symptoms of secretory or bloody diarrhea and abdominal pain. In general, chronic GVHD manifests after 100 days, and malabsorption may be present (41) . The small bowel is more commonly involved in cases of chronic GVHD than in acute cases. At CT, GVHD manifests in the gastrointestinal tract as diffuse contiguous bowel wall thickening and enhancement of the entire colon and small bowel (Fig 11) . At small bowel follow through and CT, sclerosis and fibrosis of the intestine may be seen as fixed tethered loops in patients with clinically suspected GVHD (42) . There is a high correlation between the rash associated with GVHD and the presence of GVHD in the gut. Usually, chronic GVHD does not have significant imaging findings. Treatment of GVHD includes steroid therapy, but the focus is on prevention with immunosuppressive therapy.
Pneumatosis.-Pneumatosis is a rare complication of chemotherapeutic agents such as cetuximab, etoposide, fluorouracil, and bevacizumab. In the past, it was mostly seen in those undergoing treatment for hematologic malignancies but is now seen in those undergoing treatment for solid tumors. Targeted therapies such as bevacizumab and gefitinib disrupt the molecules responsible for maintenance of normal bowel mucosa. As a result of the disruption of mucosal integrity, gas-filled cysts may form in the submucosa or subserosa of the bowel. At CT, air is seen in the bowel wall, and it may be associated with free air, portal venous air, and bowel wall thickening (Fig  12) . Pneumatosis may also be seen in asymptomatic patients with no other associated findings. In these cases, the clinician should be notified; he or she may opt to cease chemotherapy to prevent further complications. If patients are symptomatic or findings are excessive, other causes of pneumatosis should be considered.
Vessels
Vascular Complications.-Arterial and venous thromboses are complications of chemotherapy. Cisplatin-based regimens, such as that used to treat testicular cancer, are associated with Figure 11 . GVHD in a 2-year-old boy with acute lymphocytic leukemia who presented with diarrhea, abdominal pain, and gastrointestinal bleeding 60 days after undergoing single-cord blood stem-cell transplantation. Axial CT image shows diffuse thickening and enhancement of the small bowel mucosa ( * ) and thickening of the large bowel wall (arrowheads), a manifestation that is highly suspicious for GVHD. Ascites is also present. Diffuse involvement of both the small and large bowel paired with skin lesions (or other sites of GVHD) is highly suggestive of GVHD. GVHD was also present in the eyes. Grade IV GVHD was confirmed at biopsy. venous thromboembolism, arteritis, peripheral arterial occlusion, and aortic thrombosis (43) . In patients with cancer, acute arterial thrombosis has been reported with the use of anti-EGFR chemotherapy (43, 44) .
Bevacizumab and VEGF inhibitors (eg, thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) are associated with an increased risk for thromboembolism (45) . The addition of bevacizumab in conjunction with chemotherapy has been associated with a 3.6% incidence of arterial thromboembolic events compared with a 1.7% incidence for control therapy alone (46) . CT and US show a filling defect in the vessel (47) . Multiple vessels may be involved. Treatment may include anticoagulation therapy. Preventive measures include use of low-molecular-weight heparin and aspirin therapy in conjunction with chemotherapy. Caution should be exercised when treating thrombosis because of the risk for bleeding with anticoagulation therapy (45).
Bleeding.-Patients with leukemia experience the adverse side effect of gastrointestinal bleeding, a result of thrombocytopenia, during chemotherapy (48) . Recently, abdominal hemorrhage, a result of tumor necrosis and hemorrhage, was reported in patients with gastrointestinal stromal tumor who underwent imatinib therapy (49) . A clinical clue to the presence of hemorrhage is a sudden decrease in hemoglobin and hematocrit levels shortly after chemotherapy is begun. At CT, increased intratumoral hemorrhage with fluid-fluid levels and an increased tumor size may be seen (Fig 13) (50) . Other signs of hemorrhage, such as subcapsular collections and intraabdominal hematomas, may also be seen (Fig 14) . Treatment involves stopping the bleeding with embolization or surgery as needed and supportive measures with intravenous fluid administration or transfusion.
Peritoneum and Mesentery.-Both classic and newer (eg, ipilimumab and imatinib) chemotherapeutic agents may cause fluid retention and volume overload and lead to peripheral edema, Figure 13 . Hemorrhage in a 61-year-old woman with breast cancer and progressive metastatic disease to the liver who was given one dose of bevacizumab, trastuzumab, and ixabepilone therapy and presented to the emergency room with severe abdominal pain and decreased hemoglobin level (from 10 g/dL to 6 g/dL) that same evening. Axial CT image obtained at the level of the liver shows a subcapsular fluid collection with heterogeneous attenuation (40-60 HU), a finding consistent with hemorrhage, adjacent to a hepatic metastasis that is bleeding (arrow). anasarca, pleural and pericardial effusions, and ascites. Interval development of fluid in the abdomen or pelvis may indicate posttherapeutic change rather than metastatic disease (Fig 15) .
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Radiation-induced Changes Liver
The liver is at risk during irradiation for tumors of the esophagus, lung, gallbladder, and pancreas (51) . Radiation to the liver causes congestion of the central vessels of the lobule with sparing of the larger veins. Radiation-induced liver disease may occur in approximately 5%-10% of people who undergo whole-liver irradiation in doses exceeding 30-35 Gy (52). Within 2-8 weeks after radiation exposure, patients present with hepatomegaly, ascites, and elevated liver enzymes (53) . Usually, findings resolve in 3-5 months; however, radiation-induced liver disease may progress to liver failure in a small number of patients.
Radiation causes damage to endothelial cells, which leaves subendothelial cells vulnerable. This vulnerability results in platelet activation, which leads to thrombus formation, congestion of vessels, and hepatic stellate cell activation, which causes loss of hepatocytes and fibrosis. At CT, there is a clear demarcation between the irradiated area, which has low attenuation because of edema, and the nonirradiated area, a finding known as the "straight border sign." The irradiated area may also have a focal appearance that mimics that of metastasis. At MR imaging, the irradiated area has low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, a result of edema. Radiation changes may also be fluorodeoxyglucose (FDG)-avid at positron emission tomography (PET)/CT because of the inflammatory response of leukocytes (Fig 16) (54) . Imaging findings of chronic radiation injury include fibrosis and loss of volume. Chronic radiation changes in the liver may have low attenuation at CT, a result of fat changes, and low signal intensity on T1-and T2-weighted MR images. Knowledge of the radiation treatment plan is crucial to avoid misinterpreting radiation changes as metastatic disease. 
Pancreas
The pancreas is relatively radioresistant. Doses of up to 50 Gy are administered to patients with pancreatic cancer, with toxicity mainly affecting the gastrointestinal tract (55) . Acinar cells are the most radiosensitive; fibrosis, edema, and blood vessel changes may occur. Most reported cases of pancreatic injury are of the delayed or chronic variety and are characterized by massive fibrosis at pathologic analysis (56) . CT findings of radiation to the pancreas include an appearance similar to that of chronic pancreatitis due to the presence of necrosis and atrophy (57) . It may be difficult to distinguish recurrent tumor from posttreatment fibrosis if no discrete mass is present. Secondary signs of tumor, such as fat stranding, obstruction of vessels, focal enlargement, and mass or contour deformity, may help identify recurrent disease (58) .
Spleen
The spleen may be irradiated in patients undergoing treatment for lung or retroperitoneal tumors or lymphoma. The spleen is very radiosensi- tive, and effects may occur within hours at very small doses (around 4-6 Gy). At higher doses (35) (36) (37) (38) (39) (40) , splenic fibrosis and atrophy may occur. Long-term effects of radiation are functional asplenia and sepsis. No typical imaging findings are seen with acute injury. Splenic atrophy is seen in patients with late injury (59, 60) .
Stomach and Duodenum
The stomach and duodenum may be irradiated when doses of around 50 Gy are used to treat tumors of the retroperitoneum and upper abdomen. Acute findings of radiation injury include stomach ulcers and narrowing and abnormality of the antrum and pylorus (61, 62) . At upper gastrointestinal imaging and endoscopy, radiation ulcers are similar to those of peptic ulcer disease. CT may show diffuse thickening of the stomach. The duodenum may have ulcers but is usually marked by stenosis and fold thickening (60) . Complications such as perforation, gastric outlet obstruction, and hemorrhage may occur and necessitate partial gastrectomy (62) .
Small Bowel
The fixed location of the small bowel in the pelvis, especially the terminal ileum, makes it prone to radiation injury. Minimum and maximum tolerance doses for the small bowel are usually 45-65 Gy, with doses of approximately 50 Gy given over 6 weeks causing radiation enteritis. Pelvic irradiation is associated with a 5% risk for severe complications (63) . Radiation therapy may lead to ischemia of the bowel wall by causing vascular insult. Concurrent chemotherapy may heighten this reaction. At small bowel imaging, acute and subacute radiation changes manifest as "thumb printing," a result of small submucosal masses on the mesenteric border and smooth, thickened valvulae conniventes. Late radiation injury findings at small bowel studies include thickening and straightening of the wall folds, long or short or diffuse stenoses, and separation of the bowel loops (60, 64) . CT findings include bowel wall thickening with a halo sign, a serpentine appearance of the bowel, mesenteric fat stranding, and increased attenuation (from -100 to 20 HU) of the mesentery (65) . In the absence of a mass, these findings are more suggestive of radiation change than recurrent tumor. Small bowel obstruction, perforation, and fistulas may also occur as a result of radiation injury. Treatment is usually supportive; emergent findings of obstruction may require surgery.
Large Bowel and Presacral Space
The most radiosensitive portions of the colon are the cecum, rectum, and sigmoid. Side effects of radiation to the gynecologic and urologic tracts are most common in the rectum because it and the sigmoid receive close to the entire dose of radiation. Approximately 75% of patients who receive radiation to the pelvis develop symptoms such as rectal pain, bleeding, cramping, and diarrhea, and 20% of patients develop chronic proctitis (66) .
Late radiation changes, such as strictures, ulceration, protrusions, and circumferential narrowing of the bowel, may be seen at barium enema studies (Fig 17) . Radiation proctitis may be seen at CT as rectal wall thickening and perirectal fat stranding. Chronic proctitis may cause thickening of the perirectal fascia and increased thickening of the presacral space (64) .
Radiation therapy and surgery cause posttherapeutic fibrosis, fistulas, and abscesses, which, in the large bowel and presacral space, may mimic recurrent tumor (Fig 18) . CT has 50% accuracy in distinguishing recurrence from fibrosis. MR imaging may help distinguish fibrosis from recurrence, since posttherapeutic fibrosis has low signal intensity on T1-and T2-weighted images and does not demonstrate enhancement. Recurrent tumor may be seen as an enhancing mass. PET/ CT has high specificity in depicting recurrent tumor and is useful in the absence of findings at endoscopy. Recurrent tumors demonstrate FDG uptake at PET/CT (Fig 19) (67) . However, falsepositive findings may occur within 4 months of radiation therapy or surgery, a result of infectious or inflammatory conditions.
Kidney, Ureter, and Bladder
The risk for injury from radiation therapy increases when chemotherapy is simultaneously performed. Acute or chronic renal failure may result from doses of 28 Gy. Bladder changes may result from doses above 70 Gy, with late effects more common in patients who undergo radiation therapy for treatment of prostate or cervical cancer. Fistulas and sinus tracts may also occur. Ureteral strictures and fibrosis occur after . Radiation-induced hepatic angiosarcoma in a 32-year-old woman who twice underwent total abdominal radiation therapy at age 4 to treat ovarian malignant teratoma. Axial CT image shows hepatomegaly with multiple enhancing irregular masses throughout the liver. Angiosarcoma was proved at biopsy. The patient's history of abdominal radiation, the long latency period (28 years), and the pathologic finding of sarcoma are consistent with a radiation-induced tumor. With improvements in systemic chemo-and radiation therapy, patients are now living longer, which increases the chance of developing a radiation-induced secondary tumor.
brachytherapy is performed to treat gynecologic malignancies; in these cases, continued long-term surveillance is advised because the incidence of ureteral strictures and fibrosis increases with time. The most common site of stricturing is the ureterovesicular junction.
Bone
Doses as low as 16 Gy may cause marrow changes as early as 1-2 weeks after starting radiation therapy, with most changes occurring 6 months after starting low-dose radiation therapy. Radiation changes that occur in the bone are called radiation atrophy and may be distinguished from recurrent disease by a lack of enhancement, lack of a periosteal reaction, confinement to the radiation field, and a delayed manifestation after radiation therapy. Osteonecrosis may occur 1-13 years after therapy. Vertebral body collapse and compression and insufficiency fractures may also result. Insufficiency fractures are most common in the sacrum but may also occur in the pubis, clavicle, ribs, and long bones (68) .
Radiation-induced Tumors
There is a higher rate of leukemia, lymphoma, myelodysplastic disorders, and solid tumors in patients who underwent radiation therapy for treatment of a primary malignancy. Radiationinduced tumors may occur as early as 3-5 years and as late as 50 years after therapy, and the incidence increases as survival time increases. It is suspected that radiation-induced sarcoma may occur more often with IMRT than with 3D CRT because of the increased radiation dose seen in adjacent organs with IMRT (69). The criteria for diagnosing a radiation-induced tumor include a history of radiation to the area, a long latency period between the original tumor and the development of a secondary tumor, and pathologic confirmation of a sarcoma that is histologically different from the primary malignancy (70) . Softtissue tumors that are most commonly seen after radiation include malignant fibrous histiocytoma, fibrosarcoma, angiosarcoma, and leiomyosarcoma (71) . The most common radiation-induced bone tumor is osteosarcoma. CT findings of radiationinduced tumors include a new soft-tissue mass, new destruction of bone, and abnormal enhance-ment in the previously irradiated field (Figs 20,  21 ).
Summary
Oncologic patients are treated with a combination of chemotherapy, radiation therapy, and surgery. Advances in therapeutic options have greatly improved the survival of patients with cancer. Examples of these advances are newer chemotherapeutic agents that target the cell receptors and advanced radiation therapy delivery systems. It is imperative that radiologists be aware of the variety of imaging findings seen after therapy in patients with cancer. Complications may occur with classic cytotoxic therapies (eg, 5-fluorouracil), usually at higher or prolonged doses or when administered to radiosensitive areas. Newer targeted systemic agents, such as bevacizumab and imatinib, have associated characteristic toxicities because their effects on cells do not depend on dose and may manifest at imaging. Radiation may induce early and late effects in local normal tissues that may be seen at imaging. Imaging findings after chemotherapy include fatty liver, pseudocirrhosis, hepatic venoocclusive disease, and splenic rupture. Complications of radiation therapy include large and small bowel strictures and radiation-induced hepatitis and tumors. Awareness of the various therapeutic options and knowledge of the spectrum of posttherapeutic complications allows radiologists to provide a comprehensive report that may affect patient management.
